By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Halozyme Therapeutics, Inc. 

11388 Sorrento Valley Road

San Diego  California  92121  U.S.A.
Phone: 858-794-8889 Fax: 858-259-2539

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at

Key Statistics

Ownership: Public

Web Site: Halozyme
Employees: 152
Symbol: HALO

Company News
Halozyme (HALO) To Host Third Quarter 2016 Financial Results Conference Call 10/14/2016 11:51:20 AM
Halozyme (HALO) Release: PEGPH20 Selected For Inclusion In Groundbreaking Clinical Trial Initiative Designed To Transform Outcomes For Pancreatic Cancer Patients 10/4/2016 8:15:54 AM
Halozyme (HALO) To Present At The Bank of America (BAC) Merrill Lynch 2016 Global Health Care Conference 9/9/2016 8:34:06 AM
Halozyme (HALO) To Present At Upcoming Healthcare Conferences 9/1/2016 12:02:06 PM
Halozyme (HALO) Names Mark J. Gergen As Chief Operating Officer 9/1/2016 10:19:37 AM
Halozyme (HALO) Reports Second Quarter 2016 Financial Results 8/10/2016 9:53:37 AM
Eisai Inc. (ESALF.PK) And Halozyme (HALO) Initiate Phase 1b/2 Clinical Trial With First Patient Dosing Of Eribulin In Combination With PEGPH20 7/26/2016 8:03:25 AM
Halozyme (HALO) Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA 7/25/2016 7:15:02 AM
Halozyme (HALO) To Host Second Quarter 2016 Financial Results Conference Call 7/12/2016 7:50:55 AM
Halozyme (HALO) Announces Agreement To Refinance Debt, Increases 2016 Guidance For Year-End Cash Balance 6/8/2016 8:09:23 AM